



**Bridge Announces Executive Management Selections:
Appointment of CEO, Selection of CSO and Promotion of CFO**

July 30, 2007 — Gaithersburg, MD

Gaithersburg, MD — Bridge Pharmaceuticals, Inc. (Bridge) announced the hiring of a new Chief Executive Officer, Mr. D. Thomas Oakley, as well as the promotion of Mr. Patrik Jeanmonod to the position of Chief Financial Officer and the appointment of Dr. Ronald J. Marler as Chief Scientific Officer. Bridge is a global leader in preclinical contract research services with facilities in the US and China. “I am proud and excited to lead Bridge as globalization dawns in preclinical drug development,” said Mr. Oakley. “Just a few years ago, dramatically lowering research costs through globalization was only talked about. Today it is the new reality and an immense opportunity for our company. Bridge is poised for tremendous growth in demand for our services both in the US and China.”

Mr. Oakley brings a wealth of experience to Bridge with over 25 years of industry and professional experience. Prior to joining Bridge, Mr. Oakley spent nine years at Covance, Inc. where his assignments included Global Vice President Finance for the Early Development Group, Vice President of the Chemistry Division, and Global Vice President of Business Development. Most recently, Tom was the founder and President of DTO Associates, LLC, a consulting firm that worked with private equity firms and businesses in the areas of strategy, finance and management.

Mr. Patrik Jeanmonod assumes leadership as the Chief Financial Officer after holding the position of Vice President of Finance at Bridge. Patrik joined Bridge in June of 2006 and was responsible for leading the Finance and IT groups through growth and acquisition of Gene Logic Laboratories Preclinical Services Division. In addition, Patrik has been instrumental in leading the process of integrating our US and China Finance and IT operations into one global business.

Dr. Ronald Marler has been selected as Chief Scientific Officer and will continue as a member of the Board of Directors. Dr. Marler has over 27 years of experience in the pharmaceutical research and product development industries including holding positions of Division Vice-President, North America Toxicology Services at Covance Laboratories and Vice-President of Global Drug Safety at Marion Merrell Dow. In his new role as CSO at Bridge, Dr. Marler will be responsible for the scientific affairs of the company as well as advisor to the CEO and the Board.

###

Bridge Overview

Bridge Pharmaceuticals, Inc. is one of the first preclinical contract research organization (CRO) to provide US-level drug development services in both Asia and the US. Bridge is headquartered in the United States with laboratories in Gaithersburg, Maryland and Beijing, China. Bridge focuses on providing cost-effective, FDA compliant drug development services for pharmaceutical, biotech and government clients. Bridge’s current capabilities in preclinical drug development include GLP compliant toxicology, safety pharmacology, pathology and bioanalytical services. For more information, visit <http://www.bridgecro.com>.

Contact:

In USA: Marisa Pawlewicz, P: 240-364-6249; mpawlewicz@bridgecro.com

In China: Tina Huang, P: 86-10-8072-8800; thuag@bridgecro.com



Bridge Pharmaceuticals Announces Rapid-Turnaround, Flexible-Reporting Occupational Safety Testing Program for Chemical and Pharmaceutical Manufacturers

November 9, 2007 — Gaithersburg, MD

Gaithersburg, MD — Beginning December 1, 2007, Bridge Pharmaceuticals, Inc. (Bridge) will offer a new service for obtaining occupational safety studies on compound exposure during chemical manufacture and handling. With faster study turnarounds and flexible data reporting, Bridge will make it easier for companies to guard their employees against chemical exposure hazards.

Before a new compound can be manufactured, regulators require toxicology studies to judge the risks of acute exposure (i.e., exposure lasting a few minutes to a few days) to the new compound. Testing guidelines are set by the U.S. Federal Hazardous Substances Act (FHSA), Department of Transportation, and Environmental Protection Agency, the European Union's Organization for Economic Co-Operation and Development (OECD), and the Ministry of Agriculture, Forestry, and Fisheries (MAFF) in Japan. Because of the complexity of these tests and their guidelines, occupational safety chemical exposure studies often take four weeks.

At Bridge's U.S. facility in Gaithersburg, studies performed as non-GLP or fully GLP compliant will have turnarounds no longer than three weeks. Chemical, pharmaceutical, and biotech companies need occupational safety studies for thousands of compounds each year. With so many compounds to evaluate, placing studies with Bridge for whole series of compounds will mean major timesavings without compromising safety.

Bridge will further distinguish itself from competitors by offering customized reporting templates that format data however customers find most convenient. As a result, test results will be easier to interpret. By combining faster studies with more convenient reporting formats, Bridge's new Occupational Safety Program will help companies minimize compound-related occupational safety hazards more quickly and easily.

Bridge's Occupational Safety Testing Program will be open to customers worldwide. Following inauguration of the program in Gaithersburg, Bridge will offer the same services in its China facility in Beijing beginning in early 2008.

###

Bridge Overview

Bridge is one of the first preclinical contract research organization (CRO) to provide US-level drug development services in both Asia and the US. Bridge is headquartered in the United States with laboratories in Gaithersburg, Maryland and Beijing, China. Bridge focuses on providing cost-effective, FDA compliant drug development services for pharmaceutical, biotech and government clients. Bridge's current capabilities in preclinical drug development include GLP compliant toxicology, safety pharmacology, pathology and bioanalytical services. For more information, visit <http://www.bridgecro.com> or contact info@bridgecro.com.



Bridge Pharmaceuticals Names Vincent S. Lagrotteria as Vice President of Global Sales and Marketing

October 24, 2007 — Gaithersburg, MD

Gaithersburg, MD — Bridge Pharmaceuticals, Inc. (Bridge), a contract research organization (CRO) providing GLP-compliant preclinical drug development services in the US and China, announced the appointment of Vincent S. Lagrotteria to Vice President of Global Sales and Marketing, effective immediately. Mr. Lagrotteria brings to Bridge more than 20 years of healthcare sales experience in a wide variety of leadership positions.

“When we saw the breadth of Vinny’s experience and his exceptional sales achievements, we were eager to have him join us,” said Bridge CEO Tom Oakley. “We are delighted to welcome him aboard.”

“I am excited to join a company truly bridging East and West,” said Mr. Lagrotteria. “Only Bridge offers preclinical toxicology services in the US and China fully compliant to international GLP standards. But that just scratches the surface. Bridge’s unique combination of comprehensive general toxicology and hard-to-find specialty services along with years of scientific experience creates unparalleled advantages for accelerating pharmaceutical development. My goal is getting our full story in front of the customers.”

Prior to Bridge, Mr. Lagrotteria was Vice President, Global Sales and Marketing for Bilcare, a Phoenixville, PA provider of drug development services in the US, India, and the UK. Earlier, he was Vice President, Global Business Development, for Charles River Laboratories of Cary, NC and Senior Vice President of Sales, Marketing and Strategic Initiatives, for Medifacts International of Rockville, MD. His bachelor’s degree in business is from Towson State University. He earned his MBA and election to marketing honors society Mu Kappa Tau at Loyola College of Maryland.

###

Bridge Overview

Bridge Pharmaceuticals, Inc. is one of the first preclinical contract research organization (CRO) to provide US-level drug development services in both Asia and the US. Bridge is headquartered in the United States with laboratories in Gaithersburg, Maryland and Beijing, China. Bridge focuses on providing cost-effective, high-quality FDA compliant drug development services for pharmaceutical, biotech and government clients. Bridge’s current capabilities in preclinical drug development include GLP compliant toxicology, safety pharmacology, pathology and bioanalytical services. For more information, visit <http://www.bridgecro.com>.

Contact:

In USA: Marisa Pawlewicz, P: 240-364-6249; mpawlewicz@bridgecro.com

In China: Tina Huang, P: 86-10-8072-8800; tuang@bridgecro.com